Fierce Biotech and New Product Planning Summits

適応の優先順位に関する考え方を変える

This session will introduce a new and robust framework for indication prioritization that has resulted in more balanced and actionable assessments of individual indications by focusing not only on feasibility, but also post launch differentiation and value creation.  Case studies will illustrate how this change in approach has improved decision making and higher corporate valuations with less risk.

Waynne Waterfield

Managing Director,
コマーシャル・アドバイザリーグループ
Syneos Health

Separating Fact from Fiction: Decentralized Clinical Trials (DCTs) in the Biotech Space

Common misconceptions surrounding decentralized research often deter sponsors from attaining its key benefits.  Separating fact from fiction and understanding how to identify fit for purpose solutions can lay the roadmap for successful implementation of a DCT strategy. This session will focus on “myth busting” these common misconceptions and provide an overview of the benefits decentralization can bring to biotechs.

Sarah Gillespie

Associate Director,
分散化臨床試験
Syneos Health